Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Inteno expands with new software company

Inteno Group AB proudly announces the establishment of a new member in the Inteno group of companies, iopsys software solutions AB. The objective of iopsys software solutions AB is to drive the development and sales of Inteno Group’s enterprise OpenWrt based software platform for gateways, iopsys. To further associate it to iopsys background and origin, the operating system will be renamed iopsysWrt. “By establishing iopsys software solutions we show our commitment to further strengthening the position of iopsysWrt as the premier operating system in the gateway industry” says

Corona Ltd. fined by Dutch gaming authorities

Corona, a subsidiary in the Betsson Group, operating the brands Oranje and Kroon, has received a fine of EUR 300,000 from the Dutch regulator, De Kansspelautoriteit (KSA), for offering gaming to customers in the Netherlands without a local licence. Corona is assessing whether to appeal the decision. Other Betsson entities were also under investigation, but the KSA established that there were no violations with regard to them and no fines were imposed. Betsson AB acquired Corona Ltd in 2014 in anticipation of the re-regulation of the Dutch online gaming market, which according to

ExpreS2ion Biotech Holding AB: Publication of financial report for January – June 2018

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – June 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.Second quarter (2018-04-01 to 2018-06-30) · Group turnover amounted to 2,982 (2,310)* KSEK · Result after financial items amounted to -4,101 (-3,097) KSEK · Net income amounted to -3,322 (-2,636) KSEK · Net income per share** amounted to -0,28 (-0,30) SEK First half year (2018-01-01 to 2018-06-30)

Immunovia Interim report, January-June 2018

“On 3 April, trading in Immunovia’s shares started on NASDAQ Stockholm’s main market, where we are listed in the Mid Cap segment. During the second quarter we also completed a directed share issue worth around SEK 324 million to reputable institutions in Sweden and internationally. Very exciting results have been achieved in two major application areas, lung cancer and rheumatoid arthritis, which show that the general usability of the IMMray™ platform opens up great opportunities for Immunovia. During the spring and summer we completed a lung cancer study with very good results. This

Smart Eye receives five more design wins from an existing customer

Smart Eye has been awarded five more design wins from an existing customer. It is for additional car models on the same platform where two design wins have already been awarded. The European premium car manufacturer will launch these additional five car models with driver monitoring systems in 2018 and 2019.The order value is estimated to exceed 200 MSEK for the five car models based on product life cycle volume projections. A successful migration of the initial seven cars to subsequent car models for the same platform may lead to a total estimated revenue exceeding 500 MSEK over the

Camanio Care publishes interim report January - June 2018

The complete interim report is available as a pdf-file on our website www.camanio.com and is also attached to this press message.2018-08-24 Pressmessage Camanio Care Interimreport Jan-June 2018 2018-08-24 Pressmessage Camanio Care Interimreport Jan-June 2018  Summary Figures in parentheses refer to the corresponding period during the previous year, unless otherwise is stated.   1 APRIL – 30 JUNE 2018 ·  Total revenue for the period

Registration of merger, de-listing of Oncology Venture from Spotlight Stock Market, last day of trading and record date for the merger

Hoersholm, Denmark, August 24, 2018 – Oncology Venture Sweden AB (“OV”) and Medical Prognosis Institute A/S (now Oncology Venture A/S) (the “Company”) hereby announce, as part of the completion of the previously announced merger between the two companies, that the merger has been registered with the Danish Business Authority and that the Danish Business Authority has notified the Swedish Companies Registration Office (Sw. Bolagsverket) that the legal effects of the merger have commenced. As part of the registration of the merger, the share capital in the Company has been increased to

Panion’s shareholders benefit from CombiGene’s successful funding

The financing of the production development process of CombiGene’s - and therefore also Panion’s - gene therapy product is now secured, according to the press release from CombiGene on 22nd of August 2018. With the unusually large EU-contribution of 3.36 million Euro granted to CombiGene in the Horizon 2020 programme earlier this year and supplemented with the new directed shares emission, which is signed for 75% in advance, the product development is funded and can continue according to plan. It is very positive for Panion’s shareholders that CombiGene has secured the financing of

Invitation to Nokian Tyres’ Capital Markets Day on November 13, 2018

Nokian Tyres plc Press Release August 24, 2018 Nokian Tyres invites analysts and institutional investors to its Capital Markets Day on Tuesday, November 13, 2018. The event will take place in the Helsinki Music Centre (Mannerheimintie 13 A, Helsinki, Finland). The aim of the Capital Markets Day is to provide information on Nokian Tyres’ strategy and business outlook. President and CEO Hille Korhonen and other Nokian Tyres’ representatives will conduct presentations during the afternoon, providing further insights to Nokian Tyres’ strategy and business. The presentation material

Heliospectra AB (publ) Half Year Report January – June 2018

(GOTHENBURG, Sweden/SAN FRANCISCO, CA, Aug 24, 2018 – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, today presents the Half Year Report for 2018.TURNOVER AND PROFIT/LOSS JANUARY – JUNE · Order intake amounted to 30 309 (18 476) KSEK· Net sales amounted to 17 324 (11 785) KSEK.· Operating profit/loss amounted to -16 625 (-18 762) KSEK· Profit/loss after tax was -16 476 (-18 824) KSEK or -0,47 (-0,54) SEK per share. SIGNIFICANT EVENTS January –

Interim report Scandinavian Enviro Systems AB (publ) January – June 2018

MoU with Danish partner N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Q2 2018 ·  Net revenues for the period were MSEK 0.4 (0.1)  ·  Earnings after tax for the period were MSEK -10.0 (-9.5)   ·  Earnings per share for the period (before dilution) was SEK -0.08 (-0.08)   ·  Cash flow for the period after investments was MSEK -7.9 (-6.7)  ·  Signing of MoU with Treadcraft Limited regarding a plant in New York State, USA ·  Signing

Avanza launches the world’s cheapest global fund

Avanza is challenging the Swedish fund market with Avanza Global, the world’s cheapest global fund. The management fee is a low 0.05 per cent, making it cheaper and easier than ever for Swedish savers who are interested in funds.“Avanza Global is a so-called feeder fund that invests in a global index fund. After extensive research together with Morningstar*, we haven’t been able to find a cheaper equivalent fund in the market, which we are fantastically excited about,” says Åsa Mindus Söderlund, CEO of Avanza Fonder. The management fee for Avanza Global is 0.05 per cent and the total

Result of incentive program in Initiator Pharma A/S

The warrant program 2018/2020, comprising a maximum of 434,197 warrants as resolved at the Annual General Meeting of 25 May 2018, has been fully subscribed. Subscription of warrants have been submitted by employees, board members and key consultants according to Appendix 2 to the AGM protocol from 25 May, 2018. The warrants are transferred to participants at a price of SEK 0.47 per warrant, equivalent to the market value according to an external independent valuation, applying the Black & Scholes model. The warrants are subject to vesting conditions described in Appendix 4g of the AGM

The exercise period of TO4 starts today.

As part of our financing strategy and the agreement with L1 Capital, Brighter has distributed free warrants to the company's shareholders to reduce dilution. August 24 to September 10, 2018 is exercise period of Brighter Warrants TO4 during which holders of Warrants can subscribe for shares. The subscription price for the shares is SEK 6,01. Holders of warrants who have their Warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner if they want to exercise the Warrants and subscribe for the corresponding shares. Exercise of the Warrants

Interim Report Nepa AB (publ), Q2 2018

STRONG GROWTH AND IMPROVED PROFITABILITYThis is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs. SECOND QUARTER, APRIL – JUNE 2018 · Net sales increased by 18.0% to MSEK 64.9 (55.0) · Gross profit increased by 25.3% to MSEK 48.8 (38.9) · EBIT was MSEK -1.2 (-7.4) · Earnings after tax was MSEK -1.7 (-7.5) · Earnings per share was, basic SEK -0.24 (-1.05), diluted SEK -0.23 (-1.03) FIRST HALF YEAR, JANUARY – JUNE 2018 · Net sales increased by 15.5% to MSEK 122.5 (106.1) · Gross profit

Castellum’s ambitious climate targets approved by the Science Based Targets initiative

Castellum is the first Nordic real estate company to have its climate objectives approved by the Science Based Targets (SBT) initiative. Castellum’s primary goal is to reach 100% climate neutrality throughout company operations by 2030, thereby supporting the United Nations Framework Convention on Climate Change, as well as national ambitions for a fossil-free Sweden.The action-targets set by Castellum have been reviewed and approved by the Science Based Targets initiative (SBT), a joint project which includes the CDP, the United Nations Global Compact, the World Resource Initiative (WRI),

Continued expansion and a strong underlying growth

The second quarter: April – June · Net sales of SEK 273.6 (268.4) million, an increase of 1.9 percent or SEK 5.2 million. The increase was entirely organic. · Order intake of SEK 299.4 (394.8) million, a decrease of 24.1 percent · Order backlog increased by SEK 28.8 million to SEK 1 308.8 million · Operating profit of SEK 31.5 (30.8) million), an increase of 2.3 percent. Adjustment to IFRS 15 reduced operating profit by SEK 3.7 million. · Net profit after tax of SEK 23.1 (12.4) million, an increase of 87 percent. · Earnings per ordinary share of SEK 1.05 (0.91), before

Ingmar Rentzhog joins the FundedByMe board

During FundedByMe’s extraordinary shareholding meeting on August 22nd, Ingmar Rentzhog was voted in to join the FundedByMe board. Ingmar’s prior experiences from Laika Consulting AB and the finance industry, as well as from his latest venture WeDon’tHaveTime, that crowdfunded through FundedByMe, will act as a great complement to the already very established FundedByMe board. “I look forward to being able to contribute, to draw the map and to democratize the process of procuring capital. Through crowdfunding everyone is given access to where only a few had the opportunity before, to be an

3rd Quarter Results

ROYAL BANK OF CANADA Q3 2018 REPORT TO SHAREHOLDERS (PART I OF II) To view the Report to Shareholders in PDF, please click on the link below.  http://www.rns-pdf.londonstockexchange.com/rns/7555Y_1-2018-8-23.pdf Royal Bank of Canada third quarter 2018 results All amounts are in Canadian dollars and are based on financial statements prepared in compliance with International Accounting Standard 34 Interim Financial Reporting, unless otherwise noted. Effective November 1, 2017, we adopted IFRS 9 Financial Instruments. Prior period amounts are prepared in accordance with IAS 39

New step taken towards a common KYC infrastructure

In May, leading Nordic banks DNB Bank ASA, Danske Bank A/S, Nordea Bank AB (publ), Svenska Handelsbanken AB (publ) and Skandinaviska Enskilda Banken AB (publ) announced that they would jointly explore the possible establishment of a Nordic infrastructure for the Know Your Customer (KYC) process. Now, Swedbank AB (publ) has also joined the initiative."The initiative is progressing according to plan and we are moving towards our ambition of a common Nordic KYC infrastructure. Swedbank joining has made the initiative even stronger and completes the group of founding banks" says Fredrik Millde,

3rd Quarter Results

ROYAL BANK OF CANADA Q3 2018 REPORT TO SHAREHOLDERS (PART II OF II) To view the Report to Shareholders in PDF, please click on the link below. http://www.rns-pdf.londonstockexchange.com/rns/7574Y_1-2018-8-23.pdf Royal Bank of Canada third quarter 2018 results All amounts are in Canadian dollars and are based on financial statements prepared in compliance with International Accounting Standard 34 Interim Financial Reporting, unless otherwise noted. Effective November 1, 2017, we adopted IFRS 9 Financial Instruments. Prior period amounts are prepared in accordance with IAS 39

Xspray Pharma publishing Interim Report Q2, January-June 2018

“The second quarter involved continued intensive work for Xspray, primarily in-house. We executed the planned additions to our organization through successful recruitment work. I’m really satisfied with the competences the company has succeeded in bringing in. We improved all core competences necessary for late-stage drug development including regulatory affairs, quality and process validation.” Per Andersson, CEO Xspray Pharma AB (publ)Second quarter, April-June 2018 Figures in brackets are for the corresponding period of the previous year. • Profit/loss before tax was SEK –6,789,

There are no items matching the current filter
There are no more items matching the current filter
Back to top